NCT02304302View on ClinicalTrials.gov

Down Syndrome Memantine Follow-up Study

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Down SyndromeIntellectual Disability
Interventions
DRUG

Memantine

Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)

DRUG

Placebo

Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)

Trial Locations (2)

44106

University Hospitals Case Medical Center, Cleveland

05652- 900

Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo

All Listed Sponsors
collaborator

Alana USA Foundation

OTHER

lead

University Hospitals Cleveland Medical Center

OTHER

NCT02304302 - Down Syndrome Memantine Follow-up Study | Biotech Hunter | Biotech Hunter